Lenacapavir, which is administered twice yearly, was subjected to a phase three trial in which 5,300 girls and young women aged 16-25 in Uganda and South Africa participated
Read more >>>>>>>>>>>>>>>https://www.monitor.co.ug/uganda/news/national/injectable-hiv-drug-trial-returns-promising-results-4670162
